Aldo J Suria, Niccolò Crescenti, Benjamin Torner, Daniel Zimpfer, Marcus Granegger
{"title":"A 3D Print-Based Experimental Framework for the Assessment of Haemocompatibility in Rotodynamic Blood Pumps.","authors":"Aldo J Suria, Niccolò Crescenti, Benjamin Torner, Daniel Zimpfer, Marcus Granegger","doi":"10.1111/aor.70285","DOIUrl":"https://doi.org/10.1111/aor.70285","url":null,"abstract":"<p><strong>Objective: </strong>Variability of 3D-printed rotodynamic blood pumps (RBP) indicators is a crucial factor in haemocompatibility evaluation. Thus, the aim is to investigate the reproducibility of a 3D printed-based framework for further use on systematic haemocompatible studies when changing key impeller parameters in RBPs.</p><p><strong>Methods: </strong>Reproducibility was assessed in terms of standard deviation (SD), of the normalized index of haemolysis (NIH) and generated pressure head between 3 RBPs. A conventionally manufactured benchmark RBP, one 3D printed (3DP) exact replica, ( <math> <mrow><msub><mi>β</mi> <mn>2</mn></msub> <mo>=</mo> <msup><mn>79</mn> <mo>°</mo></msup> </mrow> </math> ), and one 3DP with a modification ( <math> <mrow><msub><mi>β</mi> <mn>2</mn></msub> <mo>=</mo> <msup><mn>155</mn> <mo>°</mo></msup> </mrow> </math> ) (n = 7). In vitro haemolysis experiments were carried out. Newly 3DP impellers were used for each experiment to study the manufacturing reproducibility. Moreover, pressure head-flow rate curve analysis and computational fluid dynamic (CFD) simulations were performed to support the findings.</p><p><strong>Results: </strong>The mean NIH ± SD in mg/100 L for the 3 RBPs was 4.25 ± 1.95 for the benchmark, 6.40 ± 2.68 for the exact replica, and 7.75 ± 1.87 for the modified version. Only a significant difference (p < 0.05) between the benchmark and modified version was found. Conversely, no strong statistical differences were found between the 3DP RBPs. Furthermore, SD values of pressure heads were similar between all the groups. The resulting damage index for the 3DP geometries was 2.37 (·10<sup>-4</sup>) and 2.32 (·10<sup>-4</sup>) for the replica and modified version respectively. Suggesting a probable small effect when variating <math> <mrow><msub><mi>β</mi> <mn>2</mn></msub> </mrow> </math> in free stream pumps.</p><p><strong>Conclusions: </strong>Same NIH and pressure head SD range has shown the viability of the 3DP experimental framework, proposing an economic and rapid path for systematic haemocompatibility studies of parameters in RBPs.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Design and Simulation of an AI-Powered Artificial Pancreas System With Personalized Glucose Sensing and Insulin Delivery.","authors":"G Kalyani, T Pratap, Sateesh Jasti","doi":"10.1111/aor.70278","DOIUrl":"https://doi.org/10.1111/aor.70278","url":null,"abstract":"<p><strong>Background: </strong>Achieving tight glycemic control in Type 1 diabetes is challenged by non-linear metabolic dynamics and insulin-stacking risk. Artificial intelligence models offer improved personalization, but their opacity raises safety concerns, particularly for basal insulin dosing, which is often treated as static in existing decision-support systems.</p><p><strong>Methods: </strong>We propose a hybrid closed-loop system combining a data-driven LightGBM regressor for basal dose prediction, trained on the T1D-UOM dataset, with a physiologically grounded, rule-based safety layer at the edge. Basal insulin is predicted from cyclical time encoding and glucose rate-of-change; bolus dosing follows carbohydrate intake and correction requirements. A time-bounded insulin-on-board model, an uncertainty-adaptive post-bolus damping factor, and a predictive low-glucose-suspend rule reproducing the Tandem Basal-IQ protocol together suspend or reduce delivery when residual insulin is high or hypoglycemia is projected. The system was evaluated in silico over 60 continuous days under shadow-mode replay and closed-loop reduced-order simulation, including an ablation with bolus delivery suppressed.</p><p><strong>Results: </strong>Under chronological, within-subject validation, the offline basal estimator achieved <math> <mrow><msup><mi>R</mi> <mn>2</mn></msup> <mo>=</mo> <mn>0.68</mn></mrow> </math> and <math><mrow><mi>MAE</mi> <mo>=</mo> <mn>0.21</mn></mrow> </math> U; under strict leave-one-subject-out validation on the same real cohort, performance did not generalize to unseen subjects ( <math> <mrow><msup><mi>R</mi> <mn>2</mn></msup> <mo>=</mo> <mo>-</mo> <mn>0.49</mn></mrow> </math> , <math><mrow><mi>MAE</mi> <mo>=</mo> <mn>0.49</mn></mrow> </math> U). The hybrid controller maintained Time-in-Range at 62.8% within the reduced-order closed-loop simulation, with no violations of the insulin-on-board suspension or damping rules; suppressing bolus delivery in an ablation within this simulation dropped Time-in-Range to 26.1%, indicating that, within the reduced-order model, bolus delivery is a determinant of simulated glycemic outcome.</p><p><strong>Conclusions: </strong>The proposed architecture demonstrates a safety-audited template for combining machine-learning basal prediction with clinically grounded dosing rules. Validation on real outcome data and physical hardware is identified as the next steps toward clinical translation.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Beatriz Ferreira-Alves, Joana Reis-Pardal, Nelson Cuboia, Francisco Santos-Dias, Luís Azevedo, Roberto Roncon-Albuquerque
{"title":"Impact of Extracorporeal Membrane Oxygenation Following Cardiac Arrest on Organ Donation: A Systematic Review and Meta-Analysis.","authors":"Beatriz Ferreira-Alves, Joana Reis-Pardal, Nelson Cuboia, Francisco Santos-Dias, Luís Azevedo, Roberto Roncon-Albuquerque","doi":"10.1111/aor.70284","DOIUrl":"https://doi.org/10.1111/aor.70284","url":null,"abstract":"<p><strong>Background: </strong>Organ donation following cardiac arrest (CA) increasingly contributes to the donor pool. Extracorporeal membrane oxygenation (ECMO) is used in situ for organ preservation in donation after circulatory death (DCD). ECMO is also used in refractory CA for cardiopulmonary resuscitation (ECPR), and, in selected patients with unfavorable neurological outcomes and diagnosed brain death, it can lead to donation after brain death (DBD). In this study, we performed a systematic review and meta-analysis to assess the impact of ECMO use following CA on organ donation.</p><p><strong>Methods: </strong>We searched three electronic databases (PubMed, Scopus, and Web of Science) and included single-arm and comparative studies (ECMO versus other in situ organ preservation techniques). The organ use rate per donor was assessed.</p><p><strong>Results: </strong>We included 69 primary observational studies (15 comparative). The most common clinical scenario was controlled DCD (n = 49), followed by uncontrolled DCD (n = 23), and DBD (n = 8). Multiorgan donation occurred in 88% of DBD cohorts, 46% of controlled DCD, and 22% of uncontrolled DCD. The overall meta-analytic effect measure from comparative studies showed that ECMO is associated with a higher organ use rate than other techniques (RR 1.17, 95% CI 1.01-1.36, I<sup>2</sup> = 82.4%). Subgroup analyses across clinical scenarios and comparator techniques showed that estimates favored ECMO in controlled and uncontrolled DCD, without statistical significance. In DBD post ECPR, no benefit of ECMO was observed.</p><p><strong>Conclusions: </strong>ECMO is likely superior to other techniques in controlled DCD. In uncontrolled DCD, underpowered evidence favored ECMO. In DBD following ECPR, no clear advantage of ECMO-based preservation is demonstrated.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Peng Fang, Zhongqi An, Haiquan Feng, Rundong Wang, Yating Zhang, Jinbo Wang
{"title":"Restoring Arterial Pulsatility via Speed Modulation in Ventricular Assist Devices: A Structured Narrative Review and Mechanistic Windkessel-Based Analysis.","authors":"Peng Fang, Zhongqi An, Haiquan Feng, Rundong Wang, Yating Zhang, Jinbo Wang","doi":"10.1111/aor.70286","DOIUrl":"https://doi.org/10.1111/aor.70286","url":null,"abstract":"<p><strong>Background: </strong>Continuous-flow ventricular assist devices (CF-VADs) attenuate arterial pulsatility, potentially predisposing patients to complications such as endothelial dysfunction and gastrointestinal bleeding. Speed modulation has been proposed to reconstruct arterial pulsatility, but its effectiveness and underlying mechanisms remain incompletely understood.</p><p><strong>Methods: </strong>A structured narrative review was conducted using studies identified from PubMed, Scopus, and Web of Science through June 2026. Evidence from animal experiments, mock circulatory loop studies, lumped-parameter models, and clinical investigations was synthesized. A Windkessel-based framework was used to interpret the effects of modulation parameters on arterial pulsatility.</p><p><strong>Results: </strong>Animal and computational studies generally demonstrate that speed modulation can enhance arterial pulsatility, with the enhancement depending on factors such as modulation amplitude, waveform, frequency (i.e., the duration of high- and low-speed phases) and phase relationship. Windkessel-based analysis further indicates that pulsatility enhancement is governed by differences in flow-time integrals between modulation phases, providing a mechanistic explanation for the observed effects of modulation parameters. However, clinically implemented speed modulation algorithms have not consistently produced significant improvements in arterial pulsatility or vascular function.</p><p><strong>Conclusions: </strong>Speed modulation can enhance arterial pulsatility under animal and computational conditions, but its clinical effectiveness remains limited. This discrepancy may reflect constraints on modulation amplitude and duration imposed by hemocompatibility, ventricular safety, and device reliability. Future research should integrate multiscale hemodynamic and hemocompatibility assessments, long-term animal and clinical validation, and advanced device designs and control strategies.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Moriz A Habigt, Marc Hein, Mare Mechelinck, Frederic Olbrich, Maike Stemmler, Alexander Schulz, Barbara Hammer, Sebastian Billig
{"title":"In Vivo Comparison of Algorithms Estimating Left Ventricular Stroke Work From LVAD-Derived Pump Parameters.","authors":"Moriz A Habigt, Marc Hein, Mare Mechelinck, Frederic Olbrich, Maike Stemmler, Alexander Schulz, Barbara Hammer, Sebastian Billig","doi":"10.1111/aor.70277","DOIUrl":"https://doi.org/10.1111/aor.70277","url":null,"abstract":"<p><strong>Background: </strong>Accurate assessment of cardiac work during left ventricular assist device (LVAD) therapy is essential for patient management, device explantation timing, and adaptive control algorithm development. While invasive pressure-volume methods provide accurate work and contractility assessment, their clinical applicability is limited. Non-invasive algorithms utilizing inherent pump parameters offer a promising alternative, yet no systematic comparison exists.</p><p><strong>Methods: </strong>Six non-invasive algorithms for estimating stroke work (SW) were compared in 22 healthy German Landrace pigs (48.9 ± 2.6 kg) with a Deltastream DP3 LVAD: maximal LVAD flow derivative, motor power-LV pressure relationship, pressure head-flow relationship, systolic fraction of pressure-flow area, and total/pulsatile components of pump current and flow. After isoflurane-induced heart failure, four interventions were performed: preload reduction (inferior vena cava occlusion, n = 105), afterload increase (aortic balloon occlusion, n = 97), dobutamine infusion (n = 21), and speed ramps (n = 14). Linear multilevel modeling revealed significant main effects for algorithm (χ<sup>2</sup> = 582.38), intervention type (χ<sup>2</sup> = 73.77), and their interaction (χ<sup>2</sup> = 324.80; all p < 0.001), explaining 54.04% of variability.</p><p><strong>Results: </strong>The pressure head-flow algorithm demonstrated consistently high correlations across interventions, though requiring semi-invasive pressure measurements. The pump flow area algorithm performed robustly during preload, afterload, and speed ramps but failed to capture SW changes during dobutamine. The systolic fraction algorithm achieved the highest correlations during dobutamine but frequently failed mathematical optimization, limiting applicability.</p><p><strong>Conclusion: </strong>No single algorithm performed optimally across all conditions, necessitating context-specific selection. Pronounced inter-individual variability underscores the importance of patient-specific factors. These findings provide the first systematic comparison of non-invasive SW algorithms during LVAD therapy, offering guidance for algorithm selection.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chae Rin Im, Olly Allen, A Ruth M Kappeler, Sumita Pai, Jo Pocock, Sai Bhagra, Marius Berman, Paul Lincoln, Chris Smith, Stephen Pettit
{"title":"False-Positive Hepatitis C Virus Serology Following HeartMate 3 Left Ventricular Assist Device Implantation.","authors":"Chae Rin Im, Olly Allen, A Ruth M Kappeler, Sumita Pai, Jo Pocock, Sai Bhagra, Marius Berman, Paul Lincoln, Chris Smith, Stephen Pettit","doi":"10.1111/aor.70282","DOIUrl":"https://doi.org/10.1111/aor.70282","url":null,"abstract":"<p><strong>Background: </strong>False-positive hepatitis C virus (HCV) (FPHC) serology has been reported with earlier-generation axial-flow left ventricular assist devices (LVADs), but its frequency with the magnetically levitated HeartMate 3 and its implications for heart transplant pathways remain unknown. This study describes FPHC serology in HeartMate 3 LVAD recipients and explores associated clinical and immunological features.</p><p><strong>Methods: </strong>A retrospective, single-center study was conducted at a specialist cardiothoracic center. All adults implanted with a HeartMate 3 LVAD between March 2018 and July 2025 with complete HCV serology before and after implantation were included. Patients developing HCV antibody positivity with negative confirmatory testing were classified as having FPHC serology. Patient demographics, blood product transfusions, liver function tests, lactate dehydrogenase, and human leukocyte antigen (HLA) sensitization were compared between groups.</p><p><strong>Results: </strong>Among 54 HeartMate 3 LVAD recipients, 10 (18.5%) developed FPHC serology after implantation. There were no significant differences between groups in age, sex, liver function tests, or lactate dehydrogenase. The number of fresh frozen plasma units transfused at implantation and the development of anti-HLA Class I antibodies were associated with FPHC serology (p = 0.039, p = 0.04, respectively). No significant associations were observed with red blood cell or platelet transfusions.</p><p><strong>Conclusion: </strong>FPHC serology is a clinically important phenomenon in HeartMate 3 LVAD recipients. Clinicians and patients should be aware of this phenomenon to minimize unnecessary investigations and delays to transplant candidacy assessment. Standardized confirmatory testing protocols and multicenter studies are needed to clarify the underlying immune mechanisms and their impact on post-transplant outcomes.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149376988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrew Kalra, Christopher Wilcox, Gabrielle M Knauer, Leon Fan, Akram M Zaaqoq, Bo Soo Kim, Daniel Brodie, Errol L Bush, Glenn J R Whitman, Sung-Min Cho
{"title":"Neurologic Outcomes of ECMO as a Bridge to Lung Transplantation Across Lung Allocation Policy Eras.","authors":"Andrew Kalra, Christopher Wilcox, Gabrielle M Knauer, Leon Fan, Akram M Zaaqoq, Bo Soo Kim, Daniel Brodie, Errol L Bush, Glenn J R Whitman, Sung-Min Cho","doi":"10.1111/aor.70279","DOIUrl":"https://doi.org/10.1111/aor.70279","url":null,"abstract":"<p><strong>Background: </strong>Extracorporeal membrane oxygenation (ECMO) may be used as a bridge to lung transplantation (BTT). The 2017 transition from donation service area (DSA)-based to 250-nautical mile radius-based lung allocation was designed to reduce geographic disparities, though concerns remained whether evolving patient acuity among ECMO-supported candidates could influence acute brain injury (ABI) risk. We evaluated whether the policy change was associated with increased ABI.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using the Extracorporeal Life Support Organization (2012-2023) Registry, including adults supported with respiratory ECMO as BTT. Patients were stratified relative to the DSA policy change. The primary outcome was ABI during ECMO support. The secondary outcome was in-hospital mortality; exploratory analyses compared ABI and mortality between BTT and non-BTT patients across allocation eras.</p><p><strong>Results: </strong>Among 1034 ECMO BTT patients, 256 (24.7%) were treated pre-DSA and 778 (75.3%) post-DSA. Post-DSA patients were older, had greater comorbidity burden, and exhibited more severe pre-ECMO physiologic derangement (p < 0.001 for all). ECMO duration was similar between eras (median 11 vs. 10 days, p = 0.12). Overall, 24 patients (2.3%) developed ABI: 8 (3.1%) pre-DSA and 16 (2.1%) post-DSA. Accounting for ECMO exposure time, ABI incidence was 2.06 per 1000 ECMO-days (95% CI = 0.89-4.07) pre-DSA versus 0.86 per 1000 ECMO-days (95% CI = 0.49-1.40) post-DSA, with no significant difference (incidence rate ratio = 0.42, 95% CI = 0.17-1.13). In multivariable analysis, treatment era was not independently associated with ABI (adjusted odds ratio = 1.58, 95% CI = 0.63-3.69).</p><p><strong>Conclusions: </strong>Despite treating a higher-risk population post-DSA, we observed no significant association between allocation era and ABI. These findings suggest that broader lung allocation has not increased neurologic complications among ECMO BTT patients, though ABI event rates were low.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149332227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Abstracts From the IFESS 2026 Conference.","authors":"","doi":"10.1111/aor.70228","DOIUrl":"https://doi.org/10.1111/aor.70228","url":null,"abstract":"","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 11","pages":"e1-e51"},"PeriodicalIF":2.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149294179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Artificial organsPub Date : 2026-11-01Epub Date: 2026-08-13DOI: 10.1111/aor.70225
Junichi Shimamura, Avi Levine, Stephen Pan, Gregg M Lanier, Chhaya Aggarwal, Alan Gass, David Spielvogel
{"title":"276 Days of Support by a Micro-Axial Left Ventricular Assist Device as a Bridge to Heart Transplant.","authors":"Junichi Shimamura, Avi Levine, Stephen Pan, Gregg M Lanier, Chhaya Aggarwal, Alan Gass, David Spielvogel","doi":"10.1111/aor.70225","DOIUrl":"10.1111/aor.70225","url":null,"abstract":"<p><p>The Impella 5.5 is a surgically implanted micro-axial left ventricular assist device (LVAD) increasingly utilized for mechanical circulatory support (MCS) in cardiogenic shock. While typically used for acute support up to FDA-approved 14 days, reports of prolonged utilization remain limited. We present the case of a 69-year-old male who presented with severe biventricular failure and cardiogenic shock who was bridged to heart transplantation (HT) utilizing a single Impella 5.5 for a total of 276 days. His prolonged support course was managed through a multidisciplinary approach addressing recurrent ventricular arrhythmias, renal failure, heparin-induced thrombocytopenia, and device management (suction alarms and purge flow limitations). Following successful HT, the explanted device demonstrated no mechanical injury or thrombus, and pathologic examination revealed no significant device-related structural heart damage. The patient was discharged without major complications and continued to do well at 5-month follow-up.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":"1668-1671"},"PeriodicalIF":2.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148764283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Artificial organsPub Date : 2026-10-30Epub Date: 2026-08-27DOI: 10.1111/aor.70230
Maja Munk Svendsen, Clara Kjær Hendriksen, Lars Folkersen, Peter Juhl-Olsen, Leila Louise Benhassen, Søren Nielsen Skov
{"title":"Progress Toward a Portable Artificial Lung: A Systematic Review","authors":"Maja Munk Svendsen, Clara Kjær Hendriksen, Lars Folkersen, Peter Juhl-Olsen, Leila Louise Benhassen, Søren Nielsen Skov","doi":"10.1111/aor.70230","DOIUrl":"10.1111/aor.70230","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chronic respiratory diseases are the third leading global cause of death. As lung transplantation is a definitive treatment for highly selected candidates, extracorporeal membrane oxygenation (ECMO) can be a life-sustaining therapy. Standard ECMO therapy immobilizes the patient, which increases morbidity and mortality. There is a need for a portable venovenous (VV)-ECMO device that allows hospital ambulation and ultimately home use.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This systematic review aims to identify clinically utilized and preclinical portable respiratory assist devices and describe their efficiency, progress, and innovative design features.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>A comprehensive systematic search was conducted in six databases: PubMed, Cochrane, EMBASE, Inspect Engineering Village, ScienceDirect, and <i>Journal of Heart and Lung Transplantation</i> until July 25, 2025. A total of 562 articles were screened, and 16 were included.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Eight portable respiratory assist devices were identified. Among these, the CE-marked MobyBox and the FDA-approved Breethe OXY-1 system are in clinical use. Two devices, the APL and the PAAL, are no longer in active development but have each laid the foundation for the Breethe OXY-1 system and the ModELAS device. Additionally, implementation of the PAL machine was not completed but led to the development of the double-lumen cannula. The remaining three portable ECMO devices are still undergoing preclinical testing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Several different portable ECMO devices have been developed, demonstrating substantial progress toward portable extracorporeal support. However, optimized anticoagulation strategies and safe mobilization require further investigation before widespread clinical adaptation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>PROSPERO registration number: CRD420251051796</p>\u0000 </section>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 11","pages":"1520-1531"},"PeriodicalIF":2.2,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aor.70230","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148838893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}